Blair Jordan - 08 Aug 2025 Form 4 Insider Report for 180 Life Sciences Corp. (ATNF)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ATNF
Reported as of: 08 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Aug 2025, 19:30:58 UTC
Prior SEC filing: 06 Aug 2025
Next SEC filing: 25 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Blair Jordan

Key filing fact

Blair Jordan filed Form 4 for 180 Life Sciences Corp. (ATNF) on 11 Aug 2025.

Key facts

This page summarizes Blair Jordan's Form 4 filing for 180 Life Sciences Corp. (ATNF).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Aug 2025, 19:30.

Change

Previous filing in this sequence was filed on 06 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002015193 Primary reporting owner

Jordan Blair

Relationship: Chief Executive Officer, Director
Address: 3000 EL CAMINO REAL, BLDG. 4,, SUITE 200, PALO ALTO
Signature: /s/ Blair Jordan
Signature date: 11 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATNF holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 327,576
Date: 08 Aug 2025
Ownership: Through Blair Jordan Strategy and Finance Consulting Inc.
Footnotes: F1

ATNF holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 43,166
Date: 08 Aug 2025
Ownership: See footnote
Footnotes: F2, F3

ATNF holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 200,000
Date: 08 Aug 2025
Ownership: See footnote
Footnotes: F4, F5

ATNF holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,318,000
Date: 08 Aug 2025
Ownership: See footnote
Footnotes: F6, F7

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATNF transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value: $0
Shares: +771,044
Change %
Price: $0.000000
Shares after: 771,044
Date: 08 Aug 2025
Ownership: Through Blair Jordan Strategy and Finance Consulting Inc.
Underlying class: Common Stock
Underlying amount: 771,044
Exercise price: $3.01
Footnotes: F2, F8, F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

Mr. Jordan owns and controls Blair Jordan Strategy and Finance Consulting Inc. and as such is deemed to beneficially own the securities held by such entity.

Footnote F2

On February 5, 2025, the Issuer, the Reporting Person and Dr. James Woody, entered into a Voting Agreement, whereby Dr. Woody agreed to vote a total of 43,166 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to February 5, 2026, the date after August 5, 2025, that Dr. Woody has sold all of the shares or the date that the Issuer terminates the Voting Agreement. In order to enforce the terms of the Voting Agreement, Dr. Woody provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 43,166 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.

Footnote F3

As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 43,166 shares of common stock of the Issuer held by Dr. Woody. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein.

Footnote F4

On February 21, 2025, the Issuer, the Reporting Person and Dr. Marlene Krauss, entered into a Voting Agreement, whereby Dr. Krauss agreed to vote a total of 200,000 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to August 21, 2025. In order to enforce the terms of the Voting Agreement, Dr. Krauss provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 200,000 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.

Footnote F5

As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 200,000 shares of common stock of the Issuer held by Dr. Krauss. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein.

Footnote F6

On April 28, 2025, the Issuer, the Reporting Person and Elray Resources, Inc. ("Elray") entered into a Voting Agreement, whereby Elray agreed to vote a total of 1,318,000 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to April 28, 2026. In order to enforce the terms of the Voting Agreement, Elray provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 1,318,000 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders.

Footnote F7

As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 1,318,000 shares of common stock of the Issuer held by Elray. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein.

Footnote F8

The options were granted under the 2025 Second Supplemental Option Plan of the Issuer. The options vested immediately, but are not exercisable until stockholder approval of the 2025 Second Supplemental Option Plan is received. If stockholder approval is not received prior to August 8, 2026, the options will be cancelled.

Footnote F9

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as an officer of the Issuer.